4-pivaloyl benzylamine | 62808-83-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-pivaloyl benzylamine
• 英文别名: 1-[4-(Aminomethyl)phenyl]-2,2-dimethylpropan-1-one
• CAS: 62808-83-7
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: NEUYIKGRWBERAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[4-(bromomethyl)phenyl]-2,2-dimethyl-1-propanone 、 4-pivaloyl benzylamine 生成 4'-[bis(4-pivaloylbenzyl)aminomethyl]-2,2-dimethyl-propiophenone hydrochloride 、 4",4'"-iminodimethylene-dipivalophenone hydrochloride
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Chelated PSMA inhibitors
  申请人：Cancer Targeted Technology

  公开号：US10166301B2

  公开（公告）日：2019-01-01

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文所定义的化合物可用于：(1) 检测和/或识别呈现 PSMA 的细胞的诊断方法；(2) 由本发明化合物和药学上可接受的稀释剂组成的组合物；(3) 前列腺癌细胞成像方法。
• Progesterone analogs and uses related thereto
  申请人：EMORY UNIVERSITY

  公开号：US10336787B2

  公开（公告）日：2019-07-02

  This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.

  本公开涉及黄体酮衍生物及其相关用途。在某些实施方案中，本公开涉及本文公开的化合物以及用于控制创伤性脑损伤或中风引起的炎症的用途。
• Blocking toll-like receptor 9 signaling with small molecule antagonist
  申请人：Council of Scientific & Industrial Research

  公开号：US10662177B2

  公开（公告）日：2020-05-26

  The present invention relates to small molecule 4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defense for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.

  本发明涉及小分子 4-(哌嗪-1-基)喹唑啉-2-氨基化合物，其式(I)有助于抑制某些类毒素受体（TLRs），特别是 TLR9 的信号传导。类毒素受体（TLRs）是进化保守的模式识别受体大家族的成员，是宿主免疫反应识别自我和非自我的关键第一道防线。TLR9的异常激活与不同自身免疫性疾病中的自身反应性炎症有关。本发明描述的式(I)化合物、组合物和方法可用于多种临床应用，包括作为药物制剂和方法用于治疗因TLR9活化而导致的不需要的免疫活动。
• CYCLOPENTAPEPTIDE DERIVATIVES AND USES THEREOF
  申请人：DEMMER Oliver

  公开号：US20130129622A1

  公开（公告）日：2013-05-23

  The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa 1 to Xaa 4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a detectable label; or ii) a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins and combinations thereof, with the proviso that -L-Ar-D does not comprise a 18 F-benzoyl residue.
• Chelated PSMA Inhibitors
  申请人：Cancer Targeted Technology

  公开号：US20180207298A1

  公开（公告）日：2018-07-26

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.